neoantigen-based renal cell carcinoma-poly-ICLC vaccine

{
  "id": "MLC-T-ONC-015477",
  "term": "neoantigen-based renal cell carcinoma-poly-ICLC vaccine",
  "field": "Oncology and biomedicine",
  "definition": "A peptide-based renal cell carcinoma (RCC) vaccine consisting of neoantigens and peptides derived from immunogenic epitopes identified through DNA and RNA sequencing of a patient's tumor cells, combined with the immunostimulant poly-ICLC with potential immunomodulating and antineoplastic activities. Vaccination with the neoantigen-based RCC vaccine stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, leading to tumor cell lysis. The adjuvant poly-ICLC, composed of double-stranded RNA molecules of polyinosinic-polycytidylic acid stabilized with poly L-lysine in carboxymethylcellulose, is a ligand for toll-like receptor-3 (TLR3) and induces the release of cytokines which may help to boost the immune response against the selected neoantigens.",
  "synonyms": [
    "NeoVax renal cell carcinoma vaccine",
    "NeoVax RCC vaccine"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/neoantigen-based-renal-cell-carcinoma-poly-iclc-vaccine/"
}